CANAGLIFLOZIN (canagliflozin) by Teva is sglt2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Approved for type 2 diabetes mellitus, type 1 diabetes mellitus, heart failure.
Drug data last refreshed 1mo ago
SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for…
Worked on CANAGLIFLOZIN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)